IFRXHealthcare · BiotechnologyThe 8 Wall Street analysts covering InflaRx NV hold a median 12-month price target of $8.33 — +381.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores InflaRx NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (63): Smaller than most of the companies we track.
Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IFRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +381.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | Needham | Initiates | Buy | $8.00 |
| 7 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $4.00 → $6.00 |
| 7 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 13 May 2026 | Raymond James | Upgrade | Strong Buy | — |
| 13 May 2026 | Raymond James | Upgrade | Strong Buy | $7.00 → $9.00 |
| 11 May 2026 | Cantor Fitzgerald | Maintains | Overweight | $2.00 → $4.00 |
| 11 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $6.00 → $8.00 |
| 21 Apr 2026 | Guggenheim | Reiterates | Buy | — |
| 20 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 30 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 10 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 2 Sept 2025 | HC Wainwright & Co. | Assumes | Buy | $6.00 |
| 29 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 8 May 2025 | Oppenheimer | Initiates | Outperform | — |
| 29 Apr 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 26 Mar 2025 | Guggenheim | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IFRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, InflaRx NV returned +14.6% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 99% of US stocks
Cheaper than 56% of US stocks
Cheaper than 74% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 25% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
InflaRx NV has a market value of $254.9M and an enterprise value of $108.5M.
Revenue in the twelve months to 30 June 2026: −$10K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$39.1M, a 387053.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$23.8M.
Trailing P/E: −2.6×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
InflaRx NV employs 65 people — −$155.4 of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own InflaRx NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
InflaRx announced its events calendar for November. The company is based in Jena, Germany, and is described as a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system.
Why it matters — IFRX watchers may note the company's planned investor events for November.
InflaRx announced new preclinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026. The company said the in vivo and in vitro findings showed inhibition of C5aR-mediated inflammatory responses and renal protection.
Why it matters — The findings support izicopan’s potential as a candidate for complement-driven kidney diseases, an area relevant to InflaRx’s research pipeline.
InflaRx announced it has been selected to present late-breaking pre-clinical data on its candidate izicopan at the American Society of Nephrology's Kidney Week 2026, to be held October 21-25 in Denver, Colorado.
Why it matters — A late-breaking poster selection at a major nephrology conference highlights continued scientific progress for izicopan, a key pipeline asset for InflaRx.
InflaRx N.V. announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development, effective October 1, 2026. The company develops anti-inflammatory therapeutics targeting the complement system.
Why it matters — The appointment of a new senior clinical development leader could strengthen InflaRx's clinical-stage capabilities as it advances its complement-targeting pipeline.
InflaRx has announced it will host a virtual Capital Markets Day on November 3, 2026 at 8:00 AM EST. Featured speakers at the event will include Peter A. Merkel, MD, MPH and Prof.
Why it matters — IFRX watchers may be interested as the Capital Markets Day presents an opportunity for the company to share information with investors through its featured speakers.
The 8 Wall Street analysts covering InflaRx NV have a median 12-month price target of $8.33, with estimates ranging from $4.84 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering InflaRx NV, 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InflaRx NV 9 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, InflaRx NV ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (63 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +381.4% from the last close, and Ticker Nerd's factor model ranks InflaRx NV 9 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering InflaRx NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IFRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.84 to $14 over the next 12 months.
InflaRx NV returned +14.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "InflaRx Announces November Investor Events". InflaRx announced its events calendar for November. The company is based in Jena, Germany, and is described as a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system.
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling. Its current pipeline includes vilobelimab, an intravenously administered anti-C5a antibody, and an oral C5aR inhibitor in development for inflammatory indications. InflaRx serves the biotechnology and healthcare sectors, with research and operational activities in Germany and the United States. The company’s work is centered on advancing novel treatments for severe inflammatory conditions where targeted complement inhibition may play an important therapeutic role.
CEO Prof. Niels C. Riedemann M.D., Ph.D. · 65 employees · Germany · https://www.inflarx.de
